The International Psoriasis Council (IPC) is pleased to welcome Aristea Therapeutics as a 2023 Bronze Level Corporate Member. Aristea Therapeutics is a clinical-stage drug development company based in San Diego, California. Their mission is to address the unmet medical needs of those living with autoimmune inflammatory diseases through developing new therapeutics. “On behalf of the IPC Board, Councilors, and staff, we are delighted to welcome Aristea Therapeutics as our newest Corporate Member. We look forward to working with the Aristea team to improve the care of people with Palmoplanter pustulosis (PPP) worldwide through education, research, and advocacy.,” said IPC CEO Christy Langan.
Learn more about Aristea Therapeutics.